Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 10,874 matching trials from the live ClinicalTrials.gov search.

Filters: Nashville, Tennessee Clear all

Conditions: Respiratory Syncytial Virus Infection
Interventions: Presatovir, Presatovir placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 9
States / cities: Chicago, Illinois • Annapolis, Maryland • Detroit, Michigan + 6 more

Conditions: Lymphedema
Interventions: Medical Examination, Questionnaire Administration, Shear Wave Elastography; Procedure · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 22 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Carpal Tunnel Syndrome
Interventions: Carpal tunnel release surgery; Procedure
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Metastatic or Locally Advanced Unresectable Solid Tumors
Interventions: M1069; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Hackensack, New Jersey • Nashville, Tennessee

Conditions: Crohn's Disease
Interventions: GSK1605786A; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 40
States / cities: Little Rock, Arizona • Tucson, Arizona • La Jolla, California + 35 more

Conditions: Corneal Ulcers
Interventions: Besivance 0.6% Ophthalmic Suspension, Zymaxid 0.5% Ophthalmic Solution, Vigamox 0.5% Ophthalmic Solution; Drug
Lead sponsor: Cornea Consultants Of Nashville; Other
Eligibility: 18 Years to 90 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME)
Interventions: Remigromig; Drug
Lead sponsor: EyeBiotech Ltd.; Industry
Eligibility: 50 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 27
States / cities: Phoenix, Arizona • Bakersfield, California • Modesto, California + 23 more

Conditions: Type 2 Diabetes, Obesity
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 414 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 20
States / cities: Phoenix, Arizona • Concord, California • Sacramento, California + 17 more

Conditions: PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Hormone Receptor Positive Tumor
Interventions: RLY-5836, Fulvestrant, Palbociclib, Ribociclib, Abemaciclib; Drug
Lead sponsor: Relay Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Orlando, Florida • Indianapolis, Indiana • Boston, Massachusetts + 4 more

Conditions: Headache
Interventions: Hatha yoga; Behavioral
Lead sponsor: Matthew Morris; Other
Eligibility: 13 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Epilepsy
Interventions: Diazepam; Drug
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Phoenix, Arizona • Baltimore, Maryland • Philadelphia, Pennsylvania + 1 more

Conditions: Presbycusis, Bilateral, Alzheimer Disease 2 Due to Apoe4 Isoform, Mild Cognitive Impairment
Interventions: Audiologist-based fitting, Service-only Fitting, Device-only fitting; Device
Lead sponsor: Yu-Hsiang Wu; Other
Eligibility: 55 Years to 85 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: Iowa City, Iowa • Nashville, Tennessee

Conditions: Melanoma
Interventions: trametinib, nab-paclitaxel; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Denver, Colorado • Sarasota, Florida • Nashville, Tennessee

Conditions: Epilepsy, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Biomarkers
Interventions: Not listed
Lead sponsor: Epilepsy Foundation of America; Other
Eligibility: 16 Years to 65 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 10
States / cities: San Francisco, California • New Haven, Connecticut • Miami, Florida + 6 more

Conditions: Cancer
Interventions: GSK1120212, Docetaxel + GSK1120212, Erlotinib + GSK1120212, Pemetrexed + GSK1120212, Carboplatin + GSK1120212, Nab-paclitaxel + GSK1120212, Gemcitabine + GSK1120212, Everolimus + GSK1120212; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 13
States / cities: Goodyear, Arizona • Scottsdale, Arizona • Sacramento, California + 10 more

Conditions: Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
Interventions: venipuncture, radiation therapy; Procedure · Radiation
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 34
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 26 more

Conditions: Sexual Dysfunctions, Psychological
Interventions: flibanserin, flibanserin 50mg, flibanserin 100mg, placebo; Drug
Lead sponsor: Sprout Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 1,584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 64
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 59 more

Conditions: Sedation
Interventions: Isoflurane, Propofol, Isoflurane (run-ins); Drug
Lead sponsor: Sedana Medical; Industry
Eligibility: 18 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 14
States / cities: Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois + 9 more

Conditions: Primary Sclerosing Cholangitis
Interventions: PLN-74809, Placebo; Drug
Lead sponsor: Pliant Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 21
States / cities: Pasadena, California • Redwood City, California • Sacramento, California + 17 more

Conditions: Cancer
Interventions: Regimen A, Regimen B, Regimen C, Regimen D; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Scottsdale, Arizona • Detroit, Michigan • Nashville, Tennessee + 1 more

Conditions: Stress Urinary Incontinence
Interventions: AMDC-USR (iltamiocel), Placebo; Biological · Other
Lead sponsor: Cook MyoSite; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 20
States / cities: Tucson, Arizona • La Mesa, California • Los Angeles, California + 17 more

Conditions: Cardiopulmonary Bypass, Inflammation, Fibrinolysis, Surgery
Interventions: HOE 140, Aminocaproic Acid, Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Hematologic Malignancy
Interventions: Duvelisib; Drug
Lead sponsor: SecuraBio; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 4
States / cities: Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 1 more

Search by objective public record fields.

Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection

Skin/Soft Tissue Elasticity in Head and Neck Cancer Survivors With Lymphedema and Fibrosis

Post-operative Mobilization for Carpal Tunnel Syndrome

First in Human Study of M1069 in Advanced Solid Tumors

An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.

A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Yoga for Pediatric Tension-Type Headache

A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode

Hearing Aid and Individuals With Cognitive Disorders

Study of Trametinib and Nab-paclitaxel in Patients With Melanoma

Human Epilepsy Project 2: Resistant Focal Seizures Study

GSK1120212 Rollover Study

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults

Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU1)

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor

Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence

Bradykinin Receptor Antagonism During Cardiopulmonary Bypass

A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)